RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC20H25ClN6O2S

InChIKeyUHYCLWAANUGUMN-SSEXGKCCSA-N

CAS Registry1423719-30-5

Clinical Trials associated with Nerandomilast

NCT07366034

/ Not yet recruitingPhase 3

A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)

This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary fibrosis. The purpose of this study is to understand how nerandomilast is tolerated and handled by the body and whether nerandomilast also helps children and adolescents with ILD.
For participants aged 6 to 17 years when joining, the study has 2 parts. In the first part, participants are put into 1 of 2 groups randomly, which means by chance. One group gets nerandomilast and the other group placebo. Placebo looks like nerandomilast but does not contain any medicine.
Participants are twice as likely to be in the nerandomilast group. They take tablets twice a day for 6 months. After these 6 months, in the second part of this study, they get nerandomilast for at least 2 years regardless of what they got in the first part.
Young participants aged 2 to 5 years when joining get nerandomilast from the start. They receive tablets twice a day for at least 2 and a half years.
Depending on when a person joins, the study lasts between 2 and a half years and up to 5 years. During this time, participants may visit the study site about 18 to 30 times. Study doctors collect blood samples to check participants' health and to find out how their body handles the study medicine. Doctors also check the function of the lungs, body growth, and how participants feel. The study doctors also regularly check participants' health and take note of any changes. For participants aged 6 to 17 years, the results are compared between the groups to see whether nerandomilast treatment helps children and adolescents.

Start Date27 Jul 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07321860

/ Not yet recruitingPhase 2/3

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Partial TGF-βR1 (ALK5) Inhibition With Galunisertib Combined With PDE4 Inhibition With Nerandomilast in GREM2-Positive ALS

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality. A growing body of translational and clinical evidence implicates neuroinflammation, reactive astrocytosis, and maladaptive TGF-β signaling as central contributors to disease progression. Elevated levels of Gremlin-2 (GREM2) have been identified as a marker of dysregulated TGF-β-linked astrocytic activity and fibrotic gene programs in some ALS patients, and preclinical data suggest that attenuating these pathways may mitigate glial toxicity and improve neuronal survival.
Galunisertib, a selective ATP-competitive TGF-β receptor type I (TGF-βR1/ALK5) inhibitor, has been developed to block SMAD2/3 phosphorylation and TGF-β-mediated transcriptional programs. Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades. Preclinical models show that PDE4 inhibition and TGF-β pathway blockade concurrently reduce maladaptive glial phenotypes and fibrotic mediators.
This study investigates the combination of galunisertib + nerandomilast in ALS patients with elevated GREM2, hypothesizing that dual targeting of TGF-β-mediated astrocytic reactivity and PDE4B-regulated inflammatory signaling will translate into slowing of disease progression and favorable pharmacodynamic effects on central biomarkers of neuroinflammation and neurodegeneration.

Start Date30 Jun 2026

Sponsor / Collaborator-

NCT07497087

/ Not yet recruitingPhase 3

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Oral Nerandomilast Treatment in Patients With Systemic Sclerosis (SSc)

Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis.
Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day.
Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date09 Jun 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Nerandomilast

100 Translational Medicine associated with Nerandomilast

100 Patents (Medical) associated with Nerandomilast

Literatures (Medical) associated with Nerandomilast

01 Apr 2026·British Journal of Pharmacology

Nerandomilast, a PDE4B inhibitor, alleviates silica‐induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF‐β/Smad signalling

Article

Author: Song, Yawen ; Wang, Yuanying ; Ye, Qiao ; Sun, Di ; Dilixiati, Nafeisa ; Wang, Dongmei

Background and Purpose:

Silicosis is a major cause of occupational disease‐related morbidity and mortality worldwide, yet effective pharmacological treatments remain limited. Nerandomilast, a novel inhibitor of phosphodiesterase‐4B (PDE4B), has demonstrated anti‐fibrotic potential in idiopathic pulmonary fibrosis (IPF); however, its efficacy and mechanisms in silicosis have not been investigated.

Experimental Approach:

The therapeutic effects (and their underlying mechanisms) of PDE4B inhibition was evaluated in in models of silicosis, both in vivo (male C57BL/6N mice) and in vitro (THP‐1 macrophages and MRC‐5 cells). Single‐cell RNA sequencing, using lung tissue, was first performed to identify PDE4B as a key regulatory target in the pathogenesis of silicosis. Based on this finding, the therapeutic effects and underlying mechanisms of PDE4B inhibition were assessed using nerandomilast. Pulmonary function tests, inflammatory marker analyses and fibrosis evaluations were conducted to determine treatment efficacy. In addition, bulk RNA sequencing and transcriptomic analyses were performed to explore the molecular pathways modulated by nerandomilast.

Key Results:

PDE4B inhibition effectively prevented and attenuated silica‐induced lung inflammation in the mouse model by suppressing both canonical and non‐canonical NLRP3 inflammasome pathways in lung macrophages. Furthermore, PDE4B inhibition down‐regulated TGF‐β/Smad signalling in lung fibroblasts of silicosis, leading to a significant reduction in fibrosis‐related gene expression.

Conclusions and Implications:

These findings suggest that nerandomilast, a PDE4B inhibitor, may be a promising treatment for silicosis, which currently lacks effective therapies.

01 Jan 2026·European Respiratory Review

Mechanistic basis for the antifibrotic actions of cAMP-based therapies

Review

Author: Fortier, Sean M ; Peters-Golden, Marc

The human and economic impact of idiopathic pulmonary fibrosis and other interstitial lung diseases is enormous, and available therapies are of limited utility. A decade after the introduction of the first antifibrotic agents, two new agents are on the horizon. Nerandomilast is an inhibitor of phosphodiesterase 4B, while treprostinil is an analogue of prostacyclin. Both agents increase intracellular cAMP. Although the smooth muscle relaxant properties of agents that increase cAMP have long been leveraged for the treatment of airway and vascular diseases, potential antifibrotic actions of cAMP elevation are much less well appreciated by clinicians and researchers. The purpose of this review is to discuss the mechanistic underpinnings for a beneficial role of cAMP in fibrotic lung diseases. We briefly review the pathogenesis of fibrotic lung disease, the anatomy of the cAMP pathway, and the myriad ways in which this pathway is disrupted in fibrotic diseases. We then focus on the pleiotropic actions by which cAMP opposes the aberrant phenotypes of immune cells, fibroblasts, and epithelial cells that characterise fibrotic diseases. Finally, we highlight some unanswered questions about, and future opportunities for optimising, therapeutic interventions that leverage the cAMP pathway.

01 Jan 2026·Annals of Medicine and Surgery

Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis

Author: Hujjat, Syeda Fadak Zahra ; Chandani, Devya Khaim ; Khan, Muhammad Saad ; Chandani, Harshika Khaim ; Mahmoud, Abubakr

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with poor prognosis and limited therapeutic options. Despite the introduction of pirfenidone and nintedanib, treatment discontinuation due to adverse effects remains common, highlighting the need for better-tolerated, mechanistically distinct agents. Jascayd (nerandomilast), a first-in-class selective phosphodiesterase-4B inhibitor developed by Boehringer Ingelheim, was approved by the FDA in October 2025 for adults with IPF. By elevating intracellular cyclic adenosine monophosphate (cAMP) in inflammatory and structural lung cells, nerandomilast suppresses pro-inflammatory cytokines and fibroblast activation, producing anti-inflammatory and antifibrotic effects with improved tolerability over nonselective PDE4 inhibitors. In phase 3 FIBRONEER-IPF and FIBRONEER-ILD trials, nerandomilast significantly reduced the annual rate of forced vital capacity decline versus placebo, regardless of concomitant antifibrotic use. Common adverse effects included mild diarrhea, nausea, and fatigue, with low discontinuation rates. Long-term extension data demonstrate sustained safety and lung function preservation. Offering both monotherapy and combination potential, Jascayd establishes a new therapeutic class that targets inflammation and fibrosis concurrently, representing a pivotal advancement toward personalized, multi-pathway treatment in IPF.

News (Medical) associated with Nerandomilast

25 Mar 2026

·www.fiercepharma.com

As Boehringer touts US launches, board chairman worries EU is 'falling further behind'

While touting the uptake of new drugs Hernexeos and Jascayd in the U.S., Boehringer Ingelheim Chairman Shashank Deshpande leveled criticism of regulatory red tape in Europe, where the treatments have yet to be approved. Over the last seven months, Boehringer Ingelheim has gained approvals and label expansions in the U.S. for two of its newest products—Jascayd and Hernexeos.Back home in Europe, however, the German private company is still awaiting nods for each of the treatments.Wednesday, during its 2025 earnings presentation, Boehringer Chairman Shashank Deshpande expressed his frustration with the regulatory landscape in Europe, pointing out that it took the FDA just 44 business days to tack on a second endorsement for lung cancer drug Hernexeos.“Why is that possible in one jurisdiction or territory and why does it take six months, nine months in Europe?" Deshpande asked. Deshpande, who also serves as the chief of Boehringer’s Human Pharma division, believes the regulatory environment is hindering innovation in Europe. “We’re seeing generally, clearly a decline in European competitiveness, whichever metric we use, whether it’s clinical trials, whether it’s new drugs approved, whether it’s biotech deals,” Deshpande said. “We clearly see China increasing its innovative force or power. When we look at Europe, we have to look at the facts: They say, we used to be—especially in this country—the pharmacy of the world. And so, as we look at declining output, as we look at increasing regulation, we certainly are also worried that Europe is falling further behind.”As for the launches of the new products in the U.S., both are progressing well, according to the company.“We’re seeing very strong uptake in both brands,” Deshpande said. Jascayd is the first new treatment in more than a decade for idiopathic pulmonary fibrosis (IPF), a potentially fatal disorder that causes a buildup of scar tissue in the lungs and limits oxygen intake. As a selective phosphodiesterase-4B (PDE4B) inhibitor, Jascayd brings a new mechanism of action to the market, which is led by Boehringer’s tyrosine kinase inhibitor blockbuster Ofev, which was approved in 2014.“Feedback we’re getting is that it’s addressing unmet medical need,” Deshpande said. “We are, as far as Jascayd is concerned, tracking above the historic launch performance of Ofev and that’s always a marker for us to look at how Jascayd may perform.”Ofev, which was Boehringer’s second bestselling product in 2025, generated 3.8 billion euros ($4.3 billion) in 2025, which was up by 5% when accounting for currency fluctuations.“We’re also seeing more combination use of Ofev and Jascayd,” Deshpande added. “Having said that, of course, we do expect over the course of the next years, that Ofev sales will decline as Jascayd takes up in the market.” In December, two months after it was originally approved, Boehringer scored an FDA expansion for Jascayd to treat progressive pulmonary fibrosis. As for its performance overall, Boehringer reported sales were up by a currency-adjusted figure of 7% to 27.8 billion euros ($31.4 billion) in 2025. Human Pharma sales were up 7% as well, led by diabetes and heart failure medicine Jardiance, which accounted for sales of 8.8 billion euros ($9.9 billion), which were up 9% year over year.

Drug ApprovalBiosimilar

25 Mar 2026

·endpoints.news

Boehringer Ingelheim plans for dealmaking, obesity pipeline and R&D to counter US price pressure

Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said Wednesday. Deshpande was discussing the company’s 2025 performance on a call with members of the media. Last year, the German biopharma’s human drug sales grew 7.4% on a constant currency basis to €22.7 billion ($26.3 billion), and the company expects a similar trend this year. “We expect to grow this year on a comparable basis, adjusted for currency and extraordinary effects,” said Deshpande, who also heads Boehringer’s human pharma business unit. The company’s biggest money-makers in 2025 were once again its diabetes and heart drug Jardiance and the lung disease med Ofev. But sales in the US shrank 2% from 2024, hit by “quite substantial reductions in price” in the country. The Medicare prices of Jardiance, Ofev and the diabetes therapy Trajenta are all now negotiated under the IRA. If the impact on pricing in the US were to be excluded, finance chief Frank Hübler said, “we would have also grown there as we did in Europe and other regions.” The advent of new products could help. Boehringer has won two approvals so far this year, with the lung cancer treatment Hernexeos and the idiopathic pulmonary fibrosis drug Jascayd . It also has an obesity drug that’s drawing attention. Survodutide, which Boehringer licensed from Zealand Pharma, is in two pivotal trials, and data are due at the American Diabetes Association meeting in June. “I would expect to see good weight loss in the context of important effects on the general metabolic [health] and particularly the liver,” Boehringer’s head of innovation Paola Casarosa told Endpoints News in an interview. Pressed on what good weight loss might look like, she declined to name a target percentage, but suggested that Boehringer is focused on quality over quantity: It wants to see if patients retain more muscle than on other incretin drugs, Casarosa said. Side effect rates have also been a key differentiator for the class. The drug is unlikely to reach market before the second half of 2027 — and even that might be ambitious. How will Boehringer compete with Eli Lilly and Novo Nordisk, and possibly also new entrants such as Pfizer and Roche? “It would be sort of arrogant to expect, well, we’re going to have a molecule that’s completely different from anything else,” Casarosa said. But survodutide has the unusual mechanism of GLP-1 and glucagon agonism — making it a potentially unique approach in a world of drugs that either only target GLP-1, or go after a different set of targets. Casarosa said she hopes that its glucagon agonism could allow survodutide to be particularly useful for obesity patients who also have liver disease. Phase 3 trials in the fatty liver condition known as MASH are also due this year. Boehringer also revealed on Wednesday that another obesity asset, its triple agonist, will head into Phase 2 this year. The program is somewhat mysterious: Casarosa declined to confirm its exact mechanism, so it might not be what’s known as a triple-G — an agonist of GLP-1, GIP and glucagon — like Lilly’s retatrutide or Novo Nordisk’s UBT251 . “We are investing with full speed and energy to the next steps, because we see the potential to really have strong weight loss in the context of, in our hands, unprecedented tolerance,” Casarosa said of the drug, which is called BI 3034701. Boehringer is developing it in collaboration with the Danish biotech Gubra. Survodutide and the triple agonist entered Boehringer’s pipeline via partnering deals, and they won’t be the last assets to follow this path. The company is looking at collaboration opportunities in China, and intends to stay in its familiar therapeutic areas of cardiovascular-renal-metabolism, oncology, inflammation and respiratory, and mental and eye health. “We would be looking at innovation and how we can leverage the upcoming innovation in China, how we can leverage Chinese speed in development — but all through the lens of our existing research portfolio,” Deshpande said on the media call. Alongside external sources of new products, the company is committed to spending on in-house R&D. It now plows over 27% of its net pharmaceutical sales into R&D for human therapeutics. About 40 to 50% of Boehringer’s portfolio has some elements of external innovation, Casarosa said, whether acquisitions, licensing or use of external technologies to make the molecules. She also pointed out that through its corporate venture fund, Boehringer can help seed new technologies.

Phase 2Phase 3

25 Mar 2026

·www.biospace.com

Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025

Boehringer biopharma production Press photo Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments grew to EUR 6.4 billion, equivalent to 22.9% of group net sales 70 million patients reached in 2025, up from 66 million in 2024 Ingelheim, March 25, 2026 – Boehringer Ingelheim successfully delivered on key launches in its Human Pharma business in 2025, bringing two medicines with FDA Breakthrough Therapy designation for lung cancer and pulmonary fibrosis to market in the second half of 2025. Group net sales rose by 7.3%* to EUR 27.8 billion for the full year, supported by both the Human Pharma and Animal Health business. In 2025, Boehringer increased Research and Development (R&D) investments to EUR 6.4 billion, representing 22.9% of group net sales. The company reached 70 million patients in 2025, delivering innovative medicines to more patients than ever before. “2025 reinforced the strength of our pipeline and underscored the impact of our long-term investment in R&D. With two newly launched medicines in oncology and respiratory, we are addressing high unmet medical needs of patients, while also driving the renewal of our portfolio. Our pipeline positions us well to continue to make a real difference across important disease areas, and to bring innovative therapies to more patients than ever,” said Shashank Deshpande, Chairman of the Board of Managing Directors and responsible for Human Pharma. “As 2026 unfolds with pivotal Phase III programs and readouts as well as new launches ahead, we strive to improve the lives of patients, animals, and communities worldwide.” Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: “In volatile markets and amid regional challenges, our business proved resilient as we focused on what we do best: bringing more medicines to patients and animals. We are investing more than ever in innovation, which reflects our ambition for the next years.” Human Pharma: JARDIANC E® (empagliflozin) and OFEV® (nintedanib) continue to grow; HERNEXEOS® and JASCAYD® launched Human Pharma sales rose 7.4%* to EUR 22.7 billion, supported by strong performance in its core brands. JARDIANCE®, for the treatment of chronic kidney disease, type 2 diabetes and heart failure, grew 8.7%* to EUR 8.8 billion. Sales for OFEV®, used to treat idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases, increased 5.4%* to EUR 3.8 billion. Boehringer Ingelheim expanded its portfolio with the launch of two innovative therapies in 2025: HERNEXEOS®, an oral treatment for HER2-mutant advanced non-small cell lung cancer, was launched in the U.S. in August 2025. The company also launched JASCAYD®, which was approved in the U.S. and China for idiopathic pulmonary fibrosis (IPF) in October 2025, and for progressive pulmonary fibrosis (PPF) in December 2025. JASCAYD® represents the first new innovative therapy for IPF coming to market in more than a decade. Human Pharma R&D investments came in at EUR 5.8 billion or 27.4% of the unit’s net sales. The company continued to advance its pipeline across cardiovascular, renal and metabolic diseases (CRM), oncology, respiratory and immunology, mental health, and eye health. The pipeline today includes more than 80 projects, representing over 50 new molecular entities. Ongoing advances in Boehringer’s growing mid‑ and late‑stage pipeline are building towards a sustained wave of potential launches, positioning the company to deliver transformative impact for patients in the years to come. Animal Health: preventing the spread of transboundary animal diseases In 2025, the Animal Health business demonstrated resilience and impact, with sales rising 6.5%* to EUR 4.9 billion. Growth was driven by pet parasiticides and therapeutics, poultry, and ruminant segments, with NEXGARD® growing 8.5%* to EUR 1.4 billion, cementing its position as the industry’s top-selling parasiticide brand. The company worked side by side with farmers, veterinarians, and governments, to help combat livestock diseases such as avian influenza, foot-and-mouth disease, and bluetongue virus. Boehringer received EU Marketing Authorization under Exceptional Circumstances for two poultry vaccines, supporting producers in keeping their poultry flocks healthy and increasing preparedness for avian influenza outbreaks. In addition to the VAXXINACT® H5 avian influenza vaccine, VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine protecting chickens and turkeys against Marek’s disease, Infectious Bursal Disease and H5 avian influenza. Outlook In 2026, Boehringer expects to build on the momentum of recent years with continued progress across the Animal Health and Human Pharma pipelines and critical inflection points particularly in CRM, oncology and eye health. * sales growth numbers are adjusted for currency Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at . Attachment Boehringer biopharma production

Drug ApprovalPhase 3Breakthrough Therapy

100 Deals associated with Nerandomilast

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Progressive pulmonary fibrosis	China	Boehringer Ingelheim International GmbH	09 Dec 2025
Idiopathic Pulmonary Fibrosis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	07 Oct 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CREST Syndrome	Phase 3	-	Boehringer Ingelheim GmbH	09 Jun 2026
Scleroderma, Diffuse	Phase 3	-	Boehringer Ingelheim GmbH	09 Jun 2026
Idiopathic Interstitial Pneumonias	Phase 3	United States	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	Japan	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	Argentina	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	Australia	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	Belgium	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	Canada	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	France	Boehringer Ingelheim GmbH	10 Feb 2026
Idiopathic Interstitial Pneumonias	Phase 3	Germany	Boehringer Ingelheim GmbH	10 Feb 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05321082 (FIBRONEER-ILD, CTgov)	Phase 3	Progressive fibrotic interstitial lung disease	1,178	Placebo (Placebo)	ghirtctnog(bbqizjocbj) = bmntzpwepc njxnknqvro (dgwymekyfv, zbafbwhlct - yjnxpaubgd) View more	-	09 Jan 2026
				BI 1015550 (Nerandomilast 9 mg)	ghirtctnog(bbqizjocbj) = vnsrwqhrfu njxnknqvro (dgwymekyfv, umtgknttig - zwaxskcxkd) View more
NCT06624072 (CTgov)	Phase 1	-	15	Nerandomilast (Nerandomilast 18 mg Pediatric (Ped) Fasted State (Treatment T1))	rkxxwrbqix(bocnafpfkp) = ssumjuufuk gcjplvydtw (subusltija, NA) View more	-	08 Jan 2026
				Nerandomilast (Nerandomilast 18 mg Adult Fasted State (Reference R))	rkxxwrbqix(bocnafpfkp) = yafrdyylxk gcjplvydtw (subusltija, NA) View more
NCT06070610 (CTgov)	Phase 1	-	14	Pirfenidone+Nintedanib (Pirfenidone/Nintedanib alone (Reference))	kpljyvtrft(prytquzaxo) = jigfyvbrvd twiwdqgbtf (covapeqhor, NA) View more	-	02 Dec 2025
				Pirfenidone+Nerandomilast+Nintedanib (Pirfenidone/Nintedanib in combination with Nerandomilast (Test))	kpljyvtrft(prytquzaxo) = qhxnylucpk twiwdqgbtf (covapeqhor, NA) View more
NCT06408870 (CTgov)	Phase 1	-	64	BI 1015550 (BI 1015550 Formulation C1 (Reference, R))	rxqcbzigag(dthmenkxpu) = ekqwvxdaep isfbecvxil (oafnkrilxt, na) View more	-	01 Dec 2025
				BI 1015550 (BI 1015550 Formulation C2 (Test, T))	rxqcbzigag(dthmenkxpu) = wofbrhlape isfbecvxil (oafnkrilxt, na) View more
NCT06393127 (CTgov)	Phase 1	-	64	nerandomilast (Test treatment (T))	kxdzeijdtb(bjnszkivlm) = qntqtyuimu xtrxpkisgn (fuekildvmm, NA) View more	-	01 Dec 2025
				nerandomilast (Reference treatment (R))	kxdzeijdtb(bjnszkivlm) = gkioscjibo xtrxpkisgn (fuekildvmm, NA) View more
NCT05550636 (CTgov)	Phase 1	-	15	Midazolam (Midazolam (R))	zqiquzoaqu(bmcgguusqs) = utumuvtohl imatanzmxj (qqhiwbgzvq, NA) View more	-	01 Dec 2025
				Midazolam (T+BI 1015550 (BI 1015550 + Midazolam (T))	zqiquzoaqu(bmcgguusqs) = gzoqnfthyq imatanzmxj (qqhiwbgzvq, NA) View more
NCT06415045 (CTgov)	Phase 1	-	18	Nerandomilast (Nerandomilast fasted state (Reference (R)))	jcovwdiocw(dogbxcrwvg) = ibfihqxmdy lhgzpwfhzy (pranjncuch, NA) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast fed state (Test (T)))	jcovwdiocw(dogbxcrwvg) = enbhomhsyu lhgzpwfhzy (pranjncuch, NA) View more
NCT06139302 (CTgov)	Phase 1	-	12	Nerandomilast (Nerandomilast 9 mg)	hlzocqmgmb(bkfbqzgyyl) = mbupjwjgfr qdoowuyrnq (kwnobcsalq, 13.8) View more	-	01 Dec 2025
				Nerandomilast (Nerandomilast 18 mg)	hlzocqmgmb(bkfbqzgyyl) = lxgzqjcfhf qdoowuyrnq (kwnobcsalq, 52.8) View more
NCT05633862 (CTgov)	Phase 1	-	24	BI 1015550 (BI 1015550 9 mg)	ysvprdnpev(qkxgveovom) = ftcpvqkims sgqkynxmgb (lhewcopyrf, 19.1) View more	-	28 Nov 2025
				BI 1015550 (BI 1015550 18 mg)	ysvprdnpev(qkxgveovom) = wrpsrutekc sgqkynxmgb (lhewcopyrf, 32.6) View more
NCT03403439 (CTgov)	Phase 1	-	16	itraconazole+BI 1015550 (itraconazole + BI 1015550 (T))	urzzeqltus(dbdzifcuxb) = bzhyuochwk fkrjoiyflh (aneldzalvd, NA) View more	-	28 Nov 2025
				BI 1015550 (BI 1015550 alone (R))	urzzeqltus(dbdzifcuxb) = sqxnbvsuig fkrjoiyflh (aneldzalvd, NA) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nerandomilast

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation